Our Board.

Jan Keltjens

Chairman

As well as chairing the Board of ViCentra, Jan Keltjens currently holds a number of other non-executive Board roles, including Chairman of the Boards of JenaValve Technologies and NightBalance. He is associated with the venture capital fund INKEF (Amsterdam) and most recently served as CEO of Sapiens Steering Brain Stimulation (acquired by Medtronic in August 2014). Prior to that, Jan was the Chairman and CEO of Endosense SA (acquired by St. Jude Medical in August 2013), Executive Chairman of Surpass Medical Ltd. (acquired by Stryker Corporation in late 2012), and President and CEO of AngioDynamics Inc. (ANGO) from 2009 to 2011, and of CryoCath Technologies Inc. (TSX; CYT) from 2007 until its acquisition by Medtronic in 2009. From 2000 to 2007, he served as Worldwide General Manager of Cordis Neurovascular, a Johnson & Johnson company. Jan joined Cordis in 1995 as Vice President and Managing Director responsible for international manufacturing and distribution operations, as well as research and development. He was promoted to Vice President of European Marketing for all Cordis divisions in 1998 and Vice President of Worldwide Strategic Marketing for Cordis Cardiology, based in Miami, in 1999. Before joining Cordis, Jan led research and development departments at Unilever and was Managing Director of a group of small high tech companies.

Dirk Kersten, INKEF

Non-executive Board Member

Dirk Kersten is a Managing Director at INKEF and has 14 years of investment experience in European and US healthcare companies. He has led a series of investments in (bio)pharmaceutical and medtech companies and has previously acted as a board member at Profibrix (acquired by Medicines Company), Lanthio Pharma (acquired by Morphosys) and Ascendis Pharma (listed on Nasdaq: ASDN). Dirk currently sits on the boards of ViCentra and Audion Therapeutics. Prior to INKEF, Dirk was a partner at Gilde Healthcare Partners and responsible for managing their US investment activities, based at their Boston offices. Dirk holds a Master of Science in Physics from the University of Groningen.

Anne Portwich, LSP

Non-executive Board Member

Anne Portwich, PhD, is a Partner of LSP and has been with the firm since 2001. Anne currently serves on the supervisory boards of Mint Solutions (Netherlands) and Neuravi (Ireland). Previous board positions include Sapiens Steering Brain Stimulation (acquired by Medtronic in 2014), ActoGeniX (acquired by Intrexon in 2015) and Nexstim (IPO in 2014). Anne is a jury member of New Venture, a business plan competition for start-up companies in the Netherlands as well as a member of the evaluation panel for Tekes’ Young Innovative Growth Companies (YIC) funding program in Finland. Anne obtained an MSc in biochemistry from the University of Hanover and received her PhD from the Max Planck-Institute of Marine Microbiology in Bremen.

Jörg Neermann, LSP

Non-executive Board Member

Jörg Neermann, PhD, joined LSP as a Partner in 2007 and is based in LSP’s Munich office. Prior to joining LSP, Jörg was the Managing Director of Deutsche Bank’s Venture Capital franchise DVC, where he ran its healthcare investments for more than eight years. Previously, he worked at Atlas Ventures in Germany where he also invested in the healthcare sector. He served as a Director on the supervisory boards of a large number of companies, many of which went public or were sold to larger companies. Among others, Jörg is currently a Director at Probiodrug (a biotech company developing novel Alzheimer’s treatments), EyeSense (a German medtech company developing a CGM (continuous glucose monitoring) system for people with diabetes), and Kuros (a Swiss-based company focused on developing innovative products for tissue repair and regeneration). Jörg holds a Master’s degree and a PhD in Biotechnology from the Technical University in Braunschweig and MIT in Cambridge, US. He also studied economics at Harvard Business School, USA.

Linze Dijkstra, Health Innovations

Non-executive Board Member

Linze Dijkstra is a managing partner at Health Innovations and has 20 years of experience in healthcare. Linze sits on the board of ViCentra and is investor director at several of the portfolio companies of Health Innovations, including NovioSense (continuous glucose monitoring), NightBalance (a sleep position trainer for people with sleep apnea) and Stroke2prevent (preventing strokes during cardiac surgery). Prior to Health Innovations, Linze was Director Healthcare at ABN Amro, where he was responsible for the company’s healthcare activities in the Netherlands. Linze also worked as a healthcare-consultant at PricewaterhouseCoopers and holds a Master of Science in Business Administration from the University of Twente.

Remmert Laan

Non-executive Board Member

Remmert (Rem) Laan, is President of Diabetes Insights, LLC, a consulting company specialising in marketing and business development for manufacturers of diabetes drugs, devices and apps and he brings expert knowledge of the diabetes market to ViCentra’s Board . Prior to launching Diabetes Insights in 2015, Rem served as Executive Director of the William Sansum Diabetes Center in Santa Barbara, California. He also holds more than 15 years’ experience in diabetes device commercialisation, including insulin pump products. From 2003 to 2013, Rem served in various capacities with Roche Diabetes Care, including Vice President, External Affairs, North America, and Vice President, Insulin Delivery Systems Global Marketing and Reimbursement. While with Roche, he also invented Accu-Chek’s 360° View System – a simple way to determine the right drug, dose and timing for optimal blood sugar control – and was an early pioneer in mHealth. Rem also served as Director of Marketing for Disetronic Medical Systems from 1999 to 2003. He holds an MBA from the Tuck School at Dartmouth College and a BA in Economics from Carleton College.

Advisors to our board.

Dr. Joseph Cefai

Special Advisor to the Board and Co-Founder

The inventor and architect behind ViCentra and the Kaleido insulin infusion system, Joseph has spent the last 23 years developing diabetes-related products. Though he’s a biochemist at heart and fascinated with microtechnology, Joseph firmly believes that when it comes to developing medical devices, creating products that meet the expectations of consumers should always be the key goal – and that’s the foundation on which ViCentra is built. Prior to co-founding ViCentra, Joseph was a principle founder of Cellnovo, a company he grew from an initial investment round of £1.8 million in its predecessor concept company, Starbridge Systems, to its £7 million Series A funding as Cellnovo in 2008.